Cullinan Therapeutics (CGEM), Taiho Pharmaceutical and Taiho Oncology said late Tuesday a phase 1/2 clinical trial of zipalertinib monotherapy in certain patients with non-small cell lung cancer met its primary endpoint of overall response rate.

These results are based on the phase 2b part of the study, and the companies plan to submit for US regulatory approval in the second half of 2025, they said.